Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    " July 23, 2008":" August 22, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of Switching From Epzicom to Truvada
Condition: HIV Infection
Interventions: Drug: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF);   Drug: abacavir (ABC)/lamivudine (3TC)
2 Unknown  Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects
Condition: HIV Infections
Intervention: Drug: Raltegravir and Abacavir/Lamivudine
3 Completed The Effect of Vitamin D and Calcium on Bone in Pediatric HIV
Conditions: HIV Infection;   Bone Mass
Intervention: Dietary Supplement: cholecalciferol plus calcium carbonate
4 Completed
Has Results
Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid
Condition: HIV Infections
Intervention: Drug: Raltegravir
5 Completed
Has Results
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Condition: HIV Infection
Interventions: Drug: Placebo;   Drug: Maraviroc
6 Completed Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
Condition: HIV Infections
Intervention: Drug: Nevirapine and Efavirenz
7 Completed Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families
Condition: HIV Infections
Interventions: Behavioral: Family Centered Advanced Care Planning (FCACP) sessions;   Behavioral: Health education control sessions
8 Completed Surveillance and Medical Help for HIV-infected Intravenous Drug Users in and Out of Prison
Condition: HIV Infections
Intervention:
9 Completed Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers
Condition: HIV Infections
Intervention: Drug: Maraviroc
10 Completed Bone Mineral Density Substudy - An Ancillary Study to MTN-003
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Emtricitabine/tenofovir disoproxil fumarate placebo;   Drug: Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate placebo
11 Completed
Has Results
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
Conditions: HIV Infections;   Fatigue
Interventions: Drug: Armodafinil;   Drug: Placebo
12 Unknown  Online Social Networking for HIV Prevention
Condition: HIV
Intervention: Behavioral: Online social networking HIV prevention
13 Completed Pregnant Women's CoOp
Condition: HIV
Interventions: Behavioral: Woman-focused intervention;   Behavioral: Treatment as Usual
14 Completed
Has Results
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
Condition: Acute HIV Infection
Interventions: Drug: Raltegravir;   Drug: Efavirenz;   Drug: Emtricitibine;   Drug: Tenofovir disoproxil once daily;   Drug: Tenofovir disoproxil twice daily
15 Completed
Has Results
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Conditions: HIV Infections;   HSV-2 Genital Herpes
Intervention: Drug: 3% SPL7013 Gel (VivaGel)
16 Completed
Has Results
Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)
Conditions: Chronic Hepatitis C;   Hepatitis C;   HIV Infections
Interventions: Biological: PEG-IFN alfa-2b;   Drug: RBV
17 Completed GSK706769/KALETRA Drug-drug Interaction Study
Conditions: Healthy Subjects;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK706769 & KALETRA
18 Completed Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
Condition: HIV
Intervention: Drug: Raltegravir
19 Terminated TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
Condition: HIV-1
Intervention: Drug: TMC278
20 Completed
Has Results
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
Condition: Human Immunodeficiency Virus Infections
Interventions: Drug: Efavirenz 600mg;   Drug: Boosted Lexiva

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.